CN104962512B - 干细胞用于减少白细胞外渗的用途 - Google Patents

干细胞用于减少白细胞外渗的用途 Download PDF

Info

Publication number
CN104962512B
CN104962512B CN201510188056.9A CN201510188056A CN104962512B CN 104962512 B CN104962512 B CN 104962512B CN 201510188056 A CN201510188056 A CN 201510188056A CN 104962512 B CN104962512 B CN 104962512B
Authority
CN
China
Prior art keywords
cell
cells
selectin
vcam
endothelial cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201510188056.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN104962512A (zh
Inventor
J·M·沃达
W·范特霍夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Healios KK
Original Assignee
ABT Holding Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ABT Holding Co filed Critical ABT Holding Co
Publication of CN104962512A publication Critical patent/CN104962512A/zh
Application granted granted Critical
Publication of CN104962512B publication Critical patent/CN104962512B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4234—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/28—Vascular endothelial cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
CN201510188056.9A 2009-07-21 2010-07-21 干细胞用于减少白细胞外渗的用途 Active CN104962512B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22730909P 2009-07-21 2009-07-21
US61/227,309 2009-07-21
CN201080041878.XA CN102625829B (zh) 2009-07-21 2010-07-21 干细胞用于减少白细胞外渗的用途
PCT/US2010/042726 WO2011011500A1 (en) 2009-07-21 2010-07-21 Use of stem cells to reduce leukocyte extravasation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201080041878.XA Division CN102625829B (zh) 2009-07-21 2010-07-21 干细胞用于减少白细胞外渗的用途

Publications (2)

Publication Number Publication Date
CN104962512A CN104962512A (zh) 2015-10-07
CN104962512B true CN104962512B (zh) 2022-09-09

Family

ID=43497499

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510188056.9A Active CN104962512B (zh) 2009-07-21 2010-07-21 干细胞用于减少白细胞外渗的用途
CN201080041878.XA Expired - Fee Related CN102625829B (zh) 2009-07-21 2010-07-21 干细胞用于减少白细胞外渗的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201080041878.XA Expired - Fee Related CN102625829B (zh) 2009-07-21 2010-07-21 干细胞用于减少白细胞外渗的用途

Country Status (12)

Country Link
US (2) US20110020293A1 (enExample)
EP (2) EP3831930A1 (enExample)
JP (7) JP6243119B2 (enExample)
KR (2) KR20180014224A (enExample)
CN (2) CN104962512B (enExample)
AU (1) AU2010276201B2 (enExample)
BR (1) BR112012001329B1 (enExample)
CA (1) CA2768576C (enExample)
DK (1) DK2456853T3 (enExample)
IL (1) IL217648B (enExample)
SG (3) SG10201913624YA (enExample)
WO (1) WO2011011500A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009205886B2 (en) 2008-01-18 2015-08-27 Katholieke Universiteit Leuven Stem cell aggregates and methods for making and using
US20130129686A1 (en) * 2009-11-19 2013-05-23 Regents Of The University Reducing Inflammation Using Cell Therapy
KR101900507B1 (ko) * 2010-02-25 2018-09-19 에이비티 홀딩 컴퍼니 혈관신생의 조절
WO2011106476A1 (en) * 2010-02-25 2011-09-01 Abt Holding Company Modulation of microglia activation
SG10201913920PA (en) 2010-05-12 2020-03-30 Abt Holding Co Modulation of splenocytes in cell therapy
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
BR112013031368B1 (pt) * 2011-06-06 2021-12-07 ReGenesys BVBA Método de expandir células ex vivo
US9901625B2 (en) 2011-10-15 2018-02-27 University Of Maryland, College Park Methods of regulating uptake and transcellular transport of leukocytes and therapeutics
WO2013123084A1 (en) * 2012-02-13 2013-08-22 Minerva Biotechnologies Corporation Method for detecting circulating fetal cells
IL289870B2 (en) 2013-04-12 2023-03-01 Lafrancesca Saverio Improving organs for transplantation
CA3177726A1 (en) 2015-05-21 2016-11-24 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
JP6757981B2 (ja) * 2015-07-02 2020-09-23 ナンヤン テクノロジカル ユニヴァーシティー 微少流体を用いる白血球および微小粒子分画
KR20180102661A (ko) 2016-01-21 2018-09-17 에이비티 홀딩 컴퍼니 상처 치유를 위한 줄기 세포
US20210139932A1 (en) * 2017-05-03 2021-05-13 Biomarin Pharmaceutical Inc. Improved lentiviruses for transduction of hematopoietic stem cells
WO2021194272A1 (ko) * 2020-03-25 2021-09-30 울산과학기술원 질환 상태의 백혈구를 검출하거나, 백혈구 관련 질환을 진단하는 장치 또는 방법
AU2021261282A1 (en) * 2020-04-20 2022-11-24 Longeveron Inc. Potency assay

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064748A2 (en) * 2001-02-14 2002-08-22 Furcht Leo T Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
US20060121605A1 (en) * 2003-06-03 2006-06-08 Organ Recovery Systems, Inc Selection and propagation of progenitor cells
US20060263337A1 (en) * 1999-08-05 2006-11-23 Richard Maziarz Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
CN101410125A (zh) * 2006-01-23 2009-04-15 阿特西斯公司 脑损伤和疾病的mapc治疗
US20090130124A1 (en) * 2003-09-29 2009-05-21 Varner Judith A Method for altering hematopoietic progenitor cell adhesion, differentiation, and migration

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US5192553A (en) 1987-11-12 1993-03-09 Biocyte Corporation Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
JPH04500909A (ja) 1988-09-21 1992-02-20 アニマル　バイオテクノロジー　ケンブリッジ　リミティド 家畜からの多能性胚細胞系の誘導
US7037721B1 (en) 1990-01-29 2006-05-02 Hy-Gene Biomedical, Inc. Protein-free defined media for the growth of normal human keratinocytes
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5635387A (en) 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5837539A (en) 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
US5811094A (en) 1990-11-16 1998-09-22 Osiris Therapeutics, Inc. Connective tissue regeneration using human mesenchymal stem cell preparations
GB2254289B (en) 1991-04-05 1995-03-22 Gerber Garment Technology Inc Readily transferrable adherent tape and methods of use and making
US5851832A (en) 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
WO1993009220A1 (en) 1991-11-06 1993-05-13 Correa Paulo N Cell culture medium
US5460964A (en) 1992-04-03 1995-10-24 Regents Of The University Of Minnesota Method for culturing hematopoietic cells
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
AU4543193A (en) * 1992-06-22 1994-01-24 Henry E. Young Scar inhibitory factor and use thereof
US5849553A (en) 1992-07-27 1998-12-15 California Institute Of Technology Mammalian multipotent neural stem cells
US5564183A (en) 1992-09-30 1996-10-15 Matsushita Electric Industrial Co., Ltd. Producing system of printed circuit board and method therefor
US7153684B1 (en) 1992-10-08 2006-12-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5453357A (en) 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5766951A (en) 1992-11-12 1998-06-16 Quality Biological, Inc. Serum-free medium supporting growth and proliferation of normal bone marrow cells
US5766948A (en) 1993-01-06 1998-06-16 The Regents Of The University Of California Method for production of neuroblasts
US6037174A (en) 1993-08-23 2000-03-14 Nexell Therapeutics, Inc. Preparation of serum-free suspensions of human hematopoietic cells or precursor cells
US5409813A (en) 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
US6432711B1 (en) 1993-11-03 2002-08-13 Diacrin, Inc. Embryonic stem cells capable of differentiating into desired cell lines
FR2726003B1 (fr) 1994-10-21 2002-10-18 Agronomique Inst Nat Rech Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires
US5677136A (en) 1994-11-14 1997-10-14 Systemix, Inc. Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
US5914268A (en) 1994-11-21 1999-06-22 National Jewish Center For Immunology & Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5874301A (en) 1994-11-21 1999-02-23 National Jewish Center For Immunology And Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5736396A (en) 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
GB9502022D0 (en) * 1995-02-02 1995-03-22 Abuljadayel Ilham M S A method for preparing lymphohaematopoietic progenitor cells
US5906934A (en) * 1995-03-14 1999-05-25 Morphogen Pharmaceuticals, Inc. Mesenchymal stem cells for cartilage repair
US6653134B2 (en) * 1995-03-28 2003-11-25 Cp Hahnemann University Isolated stromal cells for use in the treatment of diseases of the central nervous system
US5837670A (en) 1995-04-18 1998-11-17 Hartshorn; Richard Timothy Detergent compositions having suds suppressing properties
US5908782A (en) 1995-06-05 1999-06-01 Osiris Therapeutics, Inc. Chemically defined medium for human mesenchymal stem cells
US6015554A (en) 1995-06-07 2000-01-18 Systemix, Inc. Method of reconstituting human lymphoid and dendritic cells
EP0888377B1 (en) * 1996-03-08 2007-12-12 The Regents Of The University Of Michigan MURINE alpha(1,3)-FUCOSYLTRANSFERASE (Fuc-TVII)
US6190910B1 (en) 1996-05-21 2001-02-20 The Institute Of Physical And Chemical Research Mouse embryonic stem cell lines
US5753506A (en) 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
US5827740A (en) 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
US5945337A (en) 1996-10-18 1999-08-31 Quality Biological, Inc. Method for culturing CD34+ cells in a serum-free medium
US6361996B1 (en) 1997-05-07 2002-03-26 University Of Utah Research Foundation Neuroepithelial stem cells and glial-restricted intermediate precursors
AU7984498A (en) 1997-06-25 1999-01-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Serum-free cell growth medium
CA2294737A1 (en) 1997-07-04 1999-01-14 University Of Utah Research Foundation Neuron-restricted precursor cells
ATE307195T1 (de) * 1997-07-14 2005-11-15 Osiris Therapeutics Inc Herzmuskelregenerierung unter verwendung mesenchymaler stammzellen
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
EP1066052B1 (en) * 1998-03-18 2006-02-01 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US6368636B1 (en) * 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US6797269B2 (en) * 1998-04-03 2004-09-28 Osiris Therapeutics, Inc. Mesenchymal stem cells as immunosuppressants
SE9802264D0 (sv) * 1998-06-25 1998-06-25 Neuronova Ab A method of isolating cells
US6541247B1 (en) * 1998-06-25 2003-04-01 Neuronova Ab Method of isolating ependymal neural stem cells
DE69933579D1 (de) 1998-11-09 2006-11-23 Consorzio Per La Gestione Del Serum-freies medium für chondrozyt-ähnliche zellen
JP2002529070A (ja) 1998-11-09 2002-09-10 モナシュ・ユニヴァーシティ 胚性幹細胞
JP2002529508A (ja) * 1998-11-13 2002-09-10 オシリス セラピューティクス，インコーポレイテッド 移植における免疫応答抑制のための線維芽細胞または線維芽細胞からの上澄みを使用する方法とその組成物
US6777231B1 (en) * 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
US20050153442A1 (en) 1999-03-10 2005-07-14 Adam Katz Adipose-derived stem cells and lattices
US20050169896A1 (en) * 1999-05-14 2005-08-04 Henry Ford Health System Bone marrow transplantation for treatment of stroke
US8075881B2 (en) * 1999-08-05 2011-12-13 Regents Of The University Of Minnesota Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
US7015037B1 (en) * 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
AU7611500A (en) * 1999-09-24 2001-04-24 Abt Holding Company Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
NZ518601A (en) * 1999-09-24 2004-10-29 Morphogen Pharmaceuticals Inc Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
US20030161817A1 (en) * 2001-03-28 2003-08-28 Young Henry E. Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
US6685936B2 (en) * 1999-10-12 2004-02-03 Osiris Therapeutics, Inc. Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
EP1257282A4 (en) * 1999-12-06 2003-05-02 Gen Hospital Corp PANCREATIC STEM CELLS AND THEIR USE IN TRANSPLANTATION
US7582292B2 (en) * 2000-02-26 2009-09-01 Artecel, Inc. Adipose tissue derived stromal cells for the treatment of neurological disorders
DE60132429T2 (de) * 2000-02-26 2009-01-08 Artecel, Inc. Pluripotente aus von fettgewebe stammenden stromazellen erzeugte stammzellen und deren verwendung
CA2411914C (en) 2000-06-20 2012-08-21 Es Cell International Pte Ltd Method of controlling differentiation of embryonic stem (es) cells by culturing es cells in the presence of bmp-2 pathway antagonists
US20020061587A1 (en) * 2000-07-31 2002-05-23 Piero Anversa Methods and compositions for the repair and/or regeneration of damaged myocardium
AU2001296705A1 (en) * 2000-10-06 2002-04-15 The Regents Of The University Of California Blocking inflammation by inhibiting sialylation
US7560280B2 (en) 2000-11-03 2009-07-14 Kourion Therapeutics Gmbh Human cord blood derived unrestricted somatic stem cells (USSC)
US7311905B2 (en) * 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
DK1349918T3 (da) * 2000-12-06 2014-11-10 Anthrogenesis Corp Fremgangsmåde til indsamling af stamceller fra moderkagen
IL157350A0 (en) * 2001-02-14 2004-02-19 Anthrogenesis Corp Post-partum mammalian placenta, its use and placental stem cells therefrom
US7056738B2 (en) * 2001-03-23 2006-06-06 Tulane University Early stage multipotential stem cells in colonies of bone marrow stromal cells
KR100449141B1 (ko) * 2001-04-19 2004-09-21 (주)라이프코드 간엽 간세포를 신경세포로 분화시키는 방법
US20030003090A1 (en) * 2001-05-31 2003-01-02 Prockop Darwin J. Directed in vitro differentiation of marrow stromal cells into neural cell progenitors
KR20040030161A (ko) 2001-08-23 2004-04-08 리라이언스 라이프 사이언시스 프라이빗. 리미티드 인간 배 줄기 세포(ｈＥＳＣ)주를 확립하기 위한 내부세포 덩어리의 분리 방법
US9969980B2 (en) * 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
US6703279B2 (en) 2002-01-04 2004-03-09 Promos Technologies, Inc. Semiconductor device having contact of Si-Ge combined with cobalt silicide
WO2003064598A2 (en) 2002-01-25 2003-08-07 Genzyme Corporation Serum-free media for chondrocytes and methods of use thereof
US7145057B2 (en) 2002-02-01 2006-12-05 Origen Therapeutics, Inc. Chimeric bird from embryonic stem cells
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
WO2003080197A1 (en) 2002-03-20 2003-10-02 Sara Griffin Sports training device
GB0221481D0 (en) 2002-09-16 2002-10-23 Richards John M Grip for hand held instruments
JP2006509770A (ja) * 2002-11-26 2006-03-23 アンソロジェネシス コーポレーション 細胞治療学、細胞治療単位、およびそれらを利用した治療法
US7785601B2 (en) * 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
WO2004069172A2 (en) * 2003-01-30 2004-08-19 The Government of the United States of America as represented by the Department of Veterans Affairs Multilineage-inducible cells and uses thereof
US20040235165A1 (en) * 2003-05-19 2004-11-25 Darwin Prockop In vitro differentiation of adult stem cells
WO2005041944A2 (en) * 2003-06-27 2005-05-12 Schepens Eye Research Institute Methods and compositions for promoting axon regeneration and cell replacement therapy
US20060210544A1 (en) * 2003-06-27 2006-09-21 Renomedix Institute, Inc. Internally administered therapeutic agents for cranial nerve diseases comprising mesenchymal cells as an active ingredient
ES2552226T3 (es) * 2003-06-27 2015-11-26 DePuy Synthes Products, Inc. Reparación y regeneración de cartílago y hueso utilizando células derivadas posparto
EP1648935A2 (en) * 2003-07-25 2006-04-26 Amgen Inc. Antagonists and agonists of ldcam and methods of use
ITRM20030376A1 (it) * 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
AU2004269409A1 (en) * 2003-08-29 2005-03-10 Regents Of The University Of Minnesota Kidney derived stem cells and methods for their isolation, differentiation and use
WO2005025502A2 (en) * 2003-09-08 2005-03-24 Yeda Research And Development Co. Ltd. A method for treating or inhibiting the effects of injuries or diseases that result in neuronal degeneration
US8124072B2 (en) * 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
US20050089513A1 (en) * 2003-10-28 2005-04-28 Norio Sakuragawa Side population cells originated from human amnion and their uses
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
WO2005093044A1 (en) * 2004-03-22 2005-10-06 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
US7622108B2 (en) * 2004-04-23 2009-11-24 Bioe, Inc. Multi-lineage progenitor cells
WO2005112959A2 (en) * 2004-05-17 2005-12-01 Regents Of The University Of Minnesota Use of umbilical cord blood stem cells to treat ischemic event
CA2642826C (en) * 2006-01-23 2019-01-08 Athersys, Inc. Mapc treatment of brain injuries and diseases
US20080194637A1 (en) * 2006-11-02 2008-08-14 Curis, Inc. Small organic molecule regulators of cell proliferation
CA2700457A1 (en) * 2007-10-01 2009-04-09 Austin Smith Neural tumor stem cells and methods of use thereof
US20090130092A1 (en) * 2007-10-30 2009-05-21 Pinsky David J Nucleotide phosphate dissipation as a treatment for vascular disorders

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060263337A1 (en) * 1999-08-05 2006-11-23 Richard Maziarz Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
WO2002064748A2 (en) * 2001-02-14 2002-08-22 Furcht Leo T Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
US20060121605A1 (en) * 2003-06-03 2006-06-08 Organ Recovery Systems, Inc Selection and propagation of progenitor cells
US20090130124A1 (en) * 2003-09-29 2009-05-21 Varner Judith A Method for altering hematopoietic progenitor cell adhesion, differentiation, and migration
WO2007056578A1 (en) * 2005-11-09 2007-05-18 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
CN101336112A (zh) * 2005-11-09 2008-12-31 阿特西斯公司 多潜能成体祖细胞的免疫调节特性及其用途
CN101410125A (zh) * 2006-01-23 2009-04-15 阿特西斯公司 脑损伤和疾病的mapc治疗

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"Clinical scale expanded adult pluripotent stem cells prevent graft-versus-host disease";Magdalena Kovacsovics-Bankowski et al.;《Cellular Immunology》;20081120;第255卷;第55-60页 *
"Direct delivery of syngeneic and allogeneic large-scale expanded multipotent adult progenitor cells improves cardiac function after myocardial infarct";W Van’t Hof et al.;《Cytotherapy》;20071231;第9卷(第5期);第477-487页 *
"Inhibition of TNF-α induced ICAM-1，VCAM-1 and E-selectin expression by selenium";Fan Zhang et al.;《Atherosclerosis》;20021231;第161卷;第381-386页 *
"Interplay between telomere length and telomerase in human leukocyte differentiation and aging";Nan-ping Weng;《Journal of Leukocyte Biology》;20011231;第70卷;第861-867页 *
"Multipotent adult progenitor cells can suppress graft-versus-host disease via prostaglandin E2 synthesis and only if localized to sites of allopriming";Steven L. Highfill et al.;《Blood》;20090520;第114卷(第3期);第693-701页 *
"Multipotent adult progenitor cells: their role in wound healing and the treatment of dermal wounds";BJ Herdrich et al.;《Cytotherapy》;20081231;第10卷(第6期);第543-550页 *
"Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain";Yuehua Jiang et al.;《Experimental Hematology》;20021231;第30卷;第896-904页 *
"Pluripotency of mesenchymal stem cells derived from adult marrow";Yuehua Jiang et al.;《Nature》;20020704;第418卷;第41-49页 *
"Pre-clinical safety testing supporting clinical use of allogeneic multipotent adult progenitor cells";M Kovacsovics-Bankowski et al.;《Cytotherapy》;20081231;第10卷(第7期);第730页左栏第1段 *
"Role of Tumor Necrosis Factor-α in Graft-versus-Host Disease and Graft-versus-Leukemia Responses";Robert Korngold et al.;《Biology of Blood and Marrow Transplantation》;20031231;第9卷;第292-303页 *
"Small molecules for stem cells";Andrei Kochegarov;《Expert Opin. Ther. Patents》;20090327;第19卷(第3期);第275-281页 *
"Tumor Necrosis Factor (TNF)-α and TNF Receptors in Viral Pathogenesis";Georges Herbein et al.;《Proc. Soc. Exp. Biol. Med.》;20001231;第223卷;第241-257页 *

Also Published As

Publication number Publication date
CA2768576C (en) 2022-12-06
JP6243119B2 (ja) 2017-12-06
KR101962477B1 (ko) 2019-03-26
DK2456853T3 (da) 2021-02-01
JP2013500012A (ja) 2013-01-07
JP2023099831A (ja) 2023-07-13
EP2456853A1 (en) 2012-05-30
JP2020028298A (ja) 2020-02-27
CN102625829A (zh) 2012-08-01
BR112012001329A2 (pt) 2017-06-13
JP6325419B2 (ja) 2018-05-16
CN104962512A (zh) 2015-10-07
JP2018086011A (ja) 2018-06-07
US20140037596A1 (en) 2014-02-06
KR20120098997A (ko) 2012-09-06
KR20180014224A (ko) 2018-02-07
JP2021182941A (ja) 2021-12-02
CN102625829B (zh) 2015-05-06
BR112012001329B1 (pt) 2021-04-13
AU2010276201A1 (en) 2012-03-01
SG10201913624YA (en) 2020-03-30
JP2016129523A (ja) 2016-07-21
SG178064A1 (en) 2012-03-29
WO2011011500A1 (en) 2011-01-27
US20110020293A1 (en) 2011-01-27
EP2456853A4 (en) 2015-08-19
SG10201404280XA (en) 2014-10-30
JP2015043779A (ja) 2015-03-12
AU2010276201B2 (en) 2013-10-17
IL217648B (en) 2018-07-31
CA2768576A1 (en) 2011-01-27
EP3831930A1 (en) 2021-06-09
EP2456853B1 (en) 2020-10-28

Similar Documents

Publication Publication Date Title
CN104962512B (zh) 干细胞用于减少白细胞外渗的用途
US20140134137A1 (en) Use of Stem Cells to Reduce Leukocyte Extravasation
JP2023026662A (ja) 血管形成の調節
AU2013231210B2 (en) Use of stem cells to reduce leukocyte extravasation
HK40055177A (en) Use of stem cells to reduce leukocyte extravasation
AU2013237687B2 (en) Use of stem cells to reduce leukocyte extravasation
HK1165489A (en) Use of stem cells to reduce leukocyte extravasation
HK1165489B (en) Use of stem cells to reduce leukocyte extravasation
HK1165488A (en) Use of stem cells to reduce leukocyte extravasation
HK1165488B (en) Use of stem cells to reduce leukocyte extravasation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240801

Address after: Tokyo, Japan

Patentee after: HEALIOS Kabushiki Kaisha

Country or region after: Japan

Address before: Ohio, USA

Patentee before: ABT Holding Co.

Country or region before: U.S.A.

TG01 Patent term adjustment
TG01 Patent term adjustment